Days after Johnson & Johnson moved JNJ-78436735 into Phase III development, the company posted an interim analysis of a Phase I/IIa trial that showed a single dose of the novel coronavirus vaccine candidate induced a strong neutralizing antibody response in nearly all participants and was well-tolerated.
T cell shortage linked to severe Covid-19 in elderly; antiseptic spray may limit virus spread
Antibodies, Antiseptics, COVID-19 Antibodies, Doctors, Elderly, Immune Response, Immunoglobulin G (IgG), Infected Cells, Infected Cells, Inflammation, JAMA Otolaryngology Head and Neck Surgery, R&D, Scientists, Severe Covid-19, Studies, T-CellsA lower supply of a certain type of immune cell in older people that is critical to fighting foreign invaders may help explain their vulnerability to severe Covid-19, scientists say. An antiseptic nasal spray containing povidone-iodine may help curb transmission of the new coronavirus, preliminary research suggests.
The U.S. National Institutes of Health launched a clinical trial of fostamatinib, currently used to treat a blood platelet-destroying autoimmune disorder, in patients hospitalized with severe Covid-19.
Further coronavirus heart impact discovered; new clues to why women fare better than men
Coronavirus, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Cytokines, Food Additives, Gender Differences, Heart Disease, Heart Muscle Cells, Heart tissue, Immune Response, Men, Physics of Fluid, R&D, T-Cells, WomenA roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.
Moderna’s Covid-19 vaccine shows similar immune response in old and young
African-Americans, Agreements, American Indians, Analysis, Business, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, COVID-19 Vaccines, Immune Response, Immunizations, Interim Data, Latino, R&D, Shares, U.S. Centers for Disease Control and Prevention, U.S. governmentModerna Inc. said an analysis of the early-stage data of the company’s experimental Covid-19 vaccine showed mRNA-1273 induced immune responses in older adults that were similar to younger participants.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
COVID-19 tied to muscle-weakening disease; vaping risk documented
Annals of Internal Medicine, Brain, Coronavirus Disease 2019 (COVID-19), Coronavirus Infections, Coronavirus Vaccines, Doctors, E-Cigarettes, Illnesses, Immune Response, Journal of Adolescent Health, Masks, Medical Equipment, Muscle Wasting Disorders, Myasthenia Gravis (MG), Nervous System, Neuromuscular diseases, Researchers, Science, Scientific studies, VapingA roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.
Novavax Inc.’s experimental Covid-19 vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial, sending the company’s shares up 10%.
The University of Oxford suggested that the end of 2020 is possible for the availability of a Covid-19 vaccine candidate being developed with AstraZeneca, but expressed caution about the timeline.
German biotech firm BioNTech and U.S. drugmaker Pfizer reported additional data showing their experimental Covid-19 vaccine was safe and induced an immune response in patients.